Email a Friend
Print
Add to Outlook
Event Information
Date
11/20/2009
Time
4:00 PM
Venue
Cooper Nursing Building
CN 160
CN 160
Audience
General Audience
Current Students
Faculty
Current Students
Faculty
Additional Information
Dr. Laura Michael, Ely Lilly and Company,
'More than a bile acid receptor : FXR agonists as therapeutics'
The farnesoid X receptor (FXR, NR1H4) is a bile acid-responsive nuclear receptor that plays critical roles in the transcriptional regulation genes involved in cholesterol, bile acid, triglyceride, and carbohydrate metabolism. Because FXR has been identified as a modulator of lipid and carbohydrate metabolism, development of a synthetic FXR agonist for treatment of dyslipidemia and diabetes, two important indicators of metabolic syndrome, appears to be an attractive therapeutic approach. Evaluation of novel FXR agonists for the treatment of insulin resistance and atherosclerosis revealed unexpected mechanisms of action and a promising therapy for patients.
Contact Information
Name
Kamuel Badger, Chair
Phone
285-8820
Email
